Shattuck Labs, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Shattuck Labs, Inc. (STTK) on August 26, 2025, regarding events occurring on August 25, 2025. The filing details the closing of a securities purchase agreement with institutional accredited investors and significant changes to the composition of the Board of Directors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and the closing of a financing transaction previously disclosed on August 5, 2025.
Material Changes
- Board Resignations: Effective August 25, 2025, four directors resigned: Tyler Brous, Dr. Carrie Brownstein, Michael Lee, and Dr. Kate Sasser. The resignations were not due to disagreements regarding operations, policies, or practices.
- Board Size Reduction: The Board size was reduced from nine to seven directors, leaving two Class I directorships vacant.
- New Director Appointments: Dr. Daniel Baker and Dr. Mona Ashiya were appointed to fill the vacant Class I directorships.
- Investor Rights: The appointments were made pursuant to an agreement with OrbiMed Advisors LLC. OrbiMed, holding over 15% of outstanding shares, designated Dr. Ashiya as an OrbiMed Designee and Dr. Baker as an Independent Director Designee.
Outlook, Risks, and Management Commentary
Management confirmed the closing of the transactions contemplated by the securities purchase agreement. No specific financial guidance, risk factors, or contingencies were disclosed in this filing. The new directors received one-time stock option awards of 66,300 options each, vesting over three years, and will receive annual compensation per the Non-Employee Director Compensation Policy.
Key Facts for Investor Verification
- Verify the total capital raised and specific terms of the securities purchase agreement closed on August 25, 2025, by reviewing the August 5, 2025, Form 8-K and the attached press release.
- Confirm the updated Board composition and the specific voting rights associated with OrbiMed's designation of directors.
- Review the Company's cash position and runway following the closing of the financing, as this filing does not contain updated financial statements.
- Assess the strategic impact of the new directors' backgrounds, particularly Dr. Baker's experience in immunology and Dr. Ashiya's role at OrbiMed.